Creative trial design in RA: optimizing patient outcomes.
about
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice.Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study.[Personalised medicine. Aims and challenges].
P2860
Creative trial design in RA: optimizing patient outcomes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Creative trial design in RA: optimizing patient outcomes.
@en
Creative trial design in RA: optimizing patient outcomes.
@en-gb
Creative trial design in RA: optimizing patient outcomes.
@nl
type
label
Creative trial design in RA: optimizing patient outcomes.
@en
Creative trial design in RA: optimizing patient outcomes.
@en-gb
Creative trial design in RA: optimizing patient outcomes.
@nl
prefLabel
Creative trial design in RA: optimizing patient outcomes.
@en
Creative trial design in RA: optimizing patient outcomes.
@en-gb
Creative trial design in RA: optimizing patient outcomes.
@nl
P2860
P50
P356
P1476
Creative trial design in RA: optimizing patient outcomes.
@en
P2093
Mahesh Parmar
P2860
P2888
P304
P356
10.1038/NRRHEUM.2013.5
P407
P577
2013-02-05T00:00:00Z
P6179
1047583863